Clinical trials are the most expensive and time-consuming bottleneck in pharmaceutical development: they represent about 60% of total R&D budget and can last up to 10 years. AI is emerging as the most powerful lever to compress these times and costs without compromising patient safety.
Study design optimization
AI algorithms analyze historical data from previous trials to optimize study design: sample size, inclusion/exclusion criteria, primary and secondary endpoints. This data-driven approach reduces study failure risk — currently around 90% — and accelerates statistical significance achievement.
Intelligent patient recruitment
Patient recruitment is often the most critical limiting factor: 80% of trials don't meet enrollment targets on time. AI systems analyze electronic health records, genomic data, and health registries to proactively identify eligible patients, reducing recruitment times by 30-50%.
Real-time monitoring
AI-powered monitoring systems continuously analyze trial data to identify safety signals, protocol deviations, and result trends, enabling timely interventions and, in some cases, early trial conclusion when results are sufficiently clear.
Real World Evidence
AI is making it possible to integrate Real World Evidence (RWE) into regulatory processes, analyzing data from wearable devices, health apps, and electronic health records to complement traditional trial data.